Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0011849 (diabetes)
 277,896 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

To test the hypothesis that histamine receptors mediate increased blood-retinal barrier permeability in experimental diabetes, 51 rats were made diabetic by streptozocin injection (65 mg/kg; jugular vein) and were held for four weeks. The seven animal groups were as follows: untreated controls; untreated diabetic rats; diabetic rats receiving diphenhydramine hydrochloride (Benadryl); diabetic rats receiving cimetidine hydrochloride (Tagamet); diabetic rats receiving diphenhydramine and cimetidine; diabetic rats receiving purified pork insulin (Iletin II); and diabetic rats receiving insulin and diphenhydramine. All treatments were given during the last week. Blood-retinal barrier permeability was assessed through measurement of the vitreous content of fluorescein isothiocyanate conjugated to bovine serum albumin (FITCBSA) after 20 minutes of FITCBSA circulation. Vitreous FITCBSA content of the diabetic group was 64% greater than control content. Diabetic rats treated with either diphenhydramine or diphenhydramine and insulin had respective decreases of 43% and 40% in vitreous FITCBSA content. The vitreous content of the diabetic group receiving insulin was lowered 37% below untreated diabetic values, while the vitreous FITCBSA content of the diabetic group receiving both insulin and diphenhydramine was reduced 63%. These data indicate that retinal histamine H1-receptor activation may be partially responsible for initial blood-retinal barrier leakage of macromolecules into the vitreous and that this abnormal leakage can be prevented both by diphenhydramine and by insulin. Histamine H1 receptors may play an important role in mediating increased blood-retinal barrier permeability in experimental diabetes.
 ...
PMID:Histamine H1 receptors mediate increased blood-retinal barrier permeability in experimental diabetes. 252 87

A 33-year-old female with insulin-dependent diabetes mellitus (IDDM) for 14 yr had been taking a constant insulin dose for 2 yr. She experienced frequent hypoglycemic reactions when switched from purified pork insulin Iletin II NPH (LILLY) to Protophane (NOVO) which could not be explained by a change in either diet or body wt. A 75% reduction in dose led to a restoration of prior control. The euglycemic clamp technique was utilized to determine whether a difference in potency existed between the 2 commercially available purified pork insulins in this patient and 4 additional subjects, one of whom was not diabetic. There was an 18% difference in potency between insulins in the patient leading to these studies. A difference of more than 10% was noted in 3 of the 5 paired tests, suggesting increased potency (18, 29, 55.1%) of Actrapid (NOVO) compared with Iletin II Regular (LILLY). Until these preliminary observations are confirmed or denied, it is prudent to observe patients closely when switching from one brand of insulin to another even when the species of origin and purity are the same.
Diabetes Res 1987 Apr
PMID:Possible differences in potency of purified pork insulins: confirmation by the euglycemic clamp technique. 330 84

The hormonal content of the commercial insulins most commonly used in Canada (Connaught) and the USA (Lilly) was measured, and the prevalence of antibodies to these hormones was determined in the serum of diabetics treated with one of these preparations. Connaught insulins contained 62 +/- 10 ng pancreatic polypeptide (PP)/100 U insulin, 11 +/- 2 ng glucagon/100 U, and 56 +/- 16 pg somatostatin (SRIF)/100 U. Lilly single peak insulins contained 693 +/- 41 pg PP/100 U, 8 +/- 2 ng glucagon/100 U, and 323 +/- 174 pg SRIF/100 U, whereas the recently introduced Lilly improved single peak insulins contained 8 +/- 2 ng PP/100 U, 30 +/- 10 ng glucagon/100 U, and 43 +/- 1 pg SRIF/100 U. Lilly highly purified Iletin II pork insulin contained 1.0 ng PP/100 U, 0.4 ng glucagon/100 U, and 19 pg SRIF/100 U. Of 111 diabetics treated with Connaught insulin, 91% had antibodies to insulin, 51% had antibodies to PP, 14% had antibodies to glucagon, and 6% had antibodies to SRIF. Antibodies to PP were also found in 2 control subjects (n = 30). In patients who had taken Connaught insulin for 10 yr or more, 97% had insulin antibodies, 84% had PP antibodies, 14% had glucagon antibodies, and 11% had SRIF antibodies. Fasting serum GH levels were normal in all patients with SRIF antibodies. Cord blood from two pregnancies in insulin-treated diabetic mothers contained antibodies to the same hormones as maternal production of antibodies to insulin, PP, glucagon, and SRIF. The importance of these antibodies in the pathophysiology of diabetes is discussed.
 ...
PMID:Antibodies to insulin, pancreatic polypeptide, glucagon, and somatostatin in insulin-treated diabetics. 611 33

This study examined the suitability of commercial U.S.P. insulin as a bacterial growth medium. Purified port insulin (Iletin II, Eli Lilly & Co., Indianapolis, Indiana) was inoculated with approximately 500,000 bacteria per ml of: (1) Staphylococcus epidermidis, (2) Staphylococcus aureus, or (3) Escherichia coli. All three bacterial cultures were sterilized by the insulin within 24 h at 37 degrees C. However, Staph epidermidis was the most sensitive and Escherichia coli was least sensitive to the bactericidal effects of commercial U.S.P. insulin. Components of commercial U.S.P. insulin were then examined for their bactericidal activity against Escherichia coli. Phenol (230 mg/dl), glycerol (1.6 d/dl), and zinc cations (4.0, 2.0, and 1.0 mg/dl) demonstrated bactericidal activity, whereas dialyzed insulin demonstrated minimal effects. We conclude that insulin contaminated with 5 X 10(5) bacteria commonly found on the skin will self-sterilize within 24 h. This effect is secondary to the additives placed in the insulin and not to the insulin itself.
Diabetes 1982 Jan
PMID:Bactericidal properties of commercial U.S.P. formulated insulin. 675 10